Biomarkers in Immuno Oncology
Lodestone is currently conducting a study on the impact of Biomarkers for pre-clinical and clinical trials in the context of immuno-oncology.
We invite you to be part of this journey and would like to give you the opportunity to share your experience and expectations.
IRIS: Immunotherapy Response Indication System
Lodestone’s nanoparticle implant opens the door for a broad spectrum of longitudinal in vivo assays in the tumor microenvironment. Our small-animal system and in vivo assay technology accelerates drug development and increases the success rate of pre-clinical trials.
Answer your most critical questions before they become a problem.
… engage the intended target?
… have the intended impact on the tissue?
… create a clinically meaningful change?
… only affect a subset of the patients?
… cause adverse effects or local toxicity?